Immunotherapy with BCG and leukemic blast cells during complete remission of acute myeloid leukemia

M. Gobbi, D. Ruggero, M. Baccarani, A. Zaccaria, I. Tomasini, S. Tura

Research output: Contribution to journalArticle

Abstract

Fourteen consecutive adult patients with acute myeloid leukemia (AML), induced to complete remission (CR) with Arabinosyl Cytosine, Daunomycin, and Adriamycin have been allocated to a chemoimmunotherapy trial for remission maintenance. Immunotherapy was given as BCG and blast cells mixed together and injected intradermally during the first five months of CR, and as separate administration of BCG and blast cells thereafter. Chemotherapy consisted of five day courses of Arabinosyl Cytosine and Thioguanine, every 40 days. One year after the admission of the last patient, 10 patients have relapsed after two to eight months of CR. Four patients remain in the first continuous CR after 14, 16, 20 and 22 months respectively.

Original languageEnglish
Pages (from-to)529-536
Number of pages8
JournalHaematologica
Volume62
Issue number5
Publication statusPublished - 1977

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Gobbi, M., Ruggero, D., Baccarani, M., Zaccaria, A., Tomasini, I., & Tura, S. (1977). Immunotherapy with BCG and leukemic blast cells during complete remission of acute myeloid leukemia. Haematologica, 62(5), 529-536.